A citation-based method for searching scientific literature

Gavin P Dunn, Allen T Bruce, Hiroaki Ikeda, Lloyd J Old, Robert D Schreiber. Nat Immunol 2002
Times Cited: 3116







List of co-cited articles
724 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity




Oncology meets immunology: the cancer-immunity cycle.
Daniel S Chen, Ira Mellman. Immunity 2013
12

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
11

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
10

Neoantigens in cancer immunotherapy.
Ton N Schumacher, Robert D Schreiber. Science 2015
10

The immunobiology of cancer immunosurveillance and immunoediting.
Gavin P Dunn, Lloyd J Old, Robert D Schreiber. Immunity 2004
9

The Immune Landscape of Cancer.
Vésteinn Thorsson, David L Gibbs, Scott D Brown, Denise Wolf, Dante S Bortone, Tai-Hsien Ou Yang, Eduard Porta-Pardo, Galen F Gao, Christopher L Plaisier, James A Eddy,[...]. Immunity 2018
8


Inferring tumour purity and stromal and immune cell admixture from expression data.
Kosuke Yoshihara, Maria Shahmoradgoli, Emmanuel Martínez, Rahulsimham Vegesna, Hoon Kim, Wandaliz Torres-Garcia, Victor Treviño, Hui Shen, Peter W Laird, Douglas A Levine,[...]. Nat Commun 2013
8

Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, David F McDermott, Robert W Weber, Jeffrey A Sosman, John B Haanen, Rene Gonzalez, Caroline Robert, Dirk Schadendorf, Jessica C Hassel,[...]. N Engl J Med 2010
7

The three Es of cancer immunoediting.
Gavin P Dunn, Lloyd J Old, Robert D Schreiber. Annu Rev Immunol 2004
7

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Naiyer A Rizvi, Matthew D Hellmann, Alexandra Snyder, Pia Kvistborg, Vladimir Makarov, Jonathan J Havel, William Lee, Jianda Yuan, Phillip Wong, Teresa S Ho,[...]. Science 2015
7

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.
Padmanee Sharma, Siwen Hu-Lieskovan, Jennifer A Wargo, Antoni Ribas. Cell 2017
7

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
7

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, Scott N Gettinger, David C Smith, David F McDermott, John D Powderly, Richard D Carvajal, Jeffrey A Sosman, Michael B Atkins,[...]. N Engl J Med 2012
6


Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, Jean Jacques Grob, C Lance Cowey, Christopher D Lao, Dirk Schadendorf, Reinhard Dummer, Michael Smylie, Piotr Rutkowski,[...]. N Engl J Med 2015
6

A guide to cancer immunotherapy: from T cell basic science to clinical practice.
Alex D Waldman, Jill M Fritz, Michael J Lenardo. Nat Rev Immunol 2020
933
6


Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.
Jesse M Zaretsky, Angel Garcia-Diaz, Daniel S Shin, Helena Escuin-Ordinas, Willy Hugo, Siwen Hu-Lieskovan, Davis Y Torrejon, Gabriel Abril-Rodriguez, Salemiz Sandoval, Lucas Barthly,[...]. N Engl J Med 2016
6

Immune checkpoint blockade: a common denominator approach to cancer therapy.
Suzanne L Topalian, Charles G Drake, Drew M Pardoll. Cancer Cell 2015
6


The prognostic landscape of genes and infiltrating immune cells across human cancers.
Andrew J Gentles, Aaron M Newman, Chih Long Liu, Scott V Bratman, Weiguo Feng, Dongkyoon Kim, Viswam S Nair, Yue Xu, Amanda Khuong, Chuong D Hoang,[...]. Nat Med 2015
6

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.
Jérôme Galon, Anne Costes, Fatima Sanchez-Cabo, Amos Kirilovsky, Bernhard Mlecnik, Christine Lagorce-Pagès, Marie Tosolini, Matthieu Camus, Anne Berger, Philippe Wind,[...]. Science 2006
5

Immune surveillance of tumors.
Jeremy B Swann, Mark J Smyth. J Clin Invest 2007
898
5

PD-1 blockade induces responses by inhibiting adaptive immune resistance.
Paul C Tumeh, Christina L Harview, Jennifer H Yearley, I Peter Shintaku, Emma J M Taylor, Lidia Robert, Bartosz Chmielowski, Marko Spasic, Gina Henry, Voicu Ciobanu,[...]. Nature 2014
5

T cell exclusion, immune privilege, and the tumor microenvironment.
Johanna A Joyce, Douglas T Fearon. Science 2015
5

Macrophage plasticity and polarization: in vivo veritas.
Antonio Sica, Alberto Mantovani. J Clin Invest 2012
5


The future of immune checkpoint therapy.
Padmanee Sharma, James P Allison. Science 2015
5

Innate and adaptive immune cells in the tumor microenvironment.
Thomas F Gajewski, Hans Schreiber, Yang-Xin Fu. Nat Immunol 2013
5

Tumour-associated macrophages as treatment targets in oncology.
Alberto Mantovani, Federica Marchesi, Alberto Malesci, Luigi Laghi, Paola Allavena. Nat Rev Clin Oncol 2017
5

clusterProfiler: an R package for comparing biological themes among gene clusters.
Guangchuang Yu, Li-Gen Wang, Yanyan Han, Qing-Yu He. OMICS 2012
5

Cancer Statistics, 2021.
Rebecca L Siegel, Kimberly D Miller, Hannah E Fuchs, Ahmedin Jemal. CA Cancer J Clin 2021
5

Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
Kristian M Hargadon, Coleman E Johnson, Corey J Williams. Int Immunopharmacol 2018
552
5

Cancer statistics, 2019.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2019
5

Delivery technologies for cancer immunotherapy.
Rachel S Riley, Carl H June, Robert Langer, Michael J Mitchell. Nat Rev Drug Discov 2019
779
5

Immunity, inflammation, and cancer.
Sergei I Grivennikov, Florian R Greten, Michael Karin. Cell 2010
5

Cancer immunotherapy comes of age.
Ira Mellman, George Coukos, Glenn Dranoff. Nature 2011
5

Microenvironmental regulation of tumor progression and metastasis.
Daniela F Quail, Johanna A Joyce. Nat Med 2013
5

The concept of immunological surveillance.
F M Burnet. Prog Exp Tumor Res 1970
5

Immune escape mechanisms as a guide for cancer immunotherapy.
Gregory L Beatty, Whitney L Gladney. Clin Cancer Res 2015
530
5

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.
Shuang Qin, Linping Xu, Ming Yi, Shengnan Yu, Kongming Wu, Suxia Luo. Mol Cancer 2019
438
5

Myeloid-derived suppressor cells as regulators of the immune system.
Dmitry I Gabrilovich, Srinivas Nagaraj. Nat Rev Immunol 2009
5

PD-1 and its ligands in tolerance and immunity.
Mary E Keir, Manish J Butte, Gordon J Freeman, Arlene H Sharpe. Annu Rev Immunol 2008
5

New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape.
Deepak Mittal, Matthew M Gubin, Robert D Schreiber, Mark J Smyth. Curr Opin Immunol 2014
851
5

Molecular and cellular insights into T cell exhaustion.
E John Wherry, Makoto Kurachi. Nat Rev Immunol 2015
5

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.
Angel Garcia-Diaz, Daniel Sanghoon Shin, Blanca Homet Moreno, Justin Saco, Helena Escuin-Ordinas, Gabriel Abril Rodriguez, Jesse M Zaretsky, Lu Sun, Willy Hugo, Xiaoyan Wang,[...]. Cell Rep 2017
812
4

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy.
Spencer C Wei, Colm R Duffy, James P Allison. Cancer Discov 2018
4


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.